All In Biotech

NDA 201281 · Boehringer Ingelheim

Jentadueto

Linagliptin, Metformin Hydrochloride · Oral · Dipeptidyl Peptidase 4 Inhibitor

Last checked: Nov 19, 2026Latest source record: Aug 11, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2012

Jan 30, 2012

Approved uses

6

Original approval plus efficacy supplements

Registered trials

195

53 Phase 3, 5 recruiting

FAERS reports

1,201

655 serious, 52 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: LACTIC ACIDOSIS Postmarketing cases of metformin-associated lactic acidosis have resulted in death, hypothermia, hypotension, and resistant bradyarrhythmias. The onset of metformin-associated lactic acidosis is often subtle, accompanied only by nonspecific symptoms such as malaise, myalgias, respiratory distress, somnolence, and abdominal pain. Metformin-associated lactic acidosis was characterized by elevated blood lactate levels (>5 mmol/Liter), anion gap acidosis (without evidence of ketonuria or ketonemia), an increased lactate/pyruvate ratio; and metformin plasma levels generally >5 mcg/mL [see Warnings and Precautions (5.1) ]. Risk factors for metformin-associated lactic acidosis include renal impairment, concomitant use of certain drugs (e.g., carbonic anhydrase inhibitors such as topiramate), age 65 years old or greater, having a radiological study with contrast,...

What it is approved for

From the label in effect Aug 19, 2026.

JENTADUETO is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus . Limitations of Use JENTADUETO is not recommended in patients with type 1 diabetes mellitus. JENTADUETO has not been studied in patients with a history of pancreatitis. It is unknown whether patients with a history of pancreatitis are at an increased risk for the development of pancreatitis while using JENTADUETO [see Warnings and Precautions (5.2) ]. JENTADUETO is a combination of linagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor and metformin hydrochloride (HCl), a biguanide, indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus ( 1 ) Limitations of Use Not recommended in patients with type 1 diabetes mellitus ( 1 ) Has not been studied in patients with a history of pancreatitis ( 1 )

Mechanism: JENTADUETO JENTADUETO contains: linagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, and metformin, a biguanide. Linagliptin Linagliptin is an inhibitor of DPP-4, an enzyme that degrades the incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). Thus, linagliptin increases the concentrations of active incretin hormones, stimulating the release of insulin in a glucose-dependent manner and decreasing the levels of glucagon in the circulation. Both incretin hormones are involved in the physiological regulation of glucose homeostasis....

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

3 products under this application
  • JENTADUETO · LINAGLIPTIN 2.5MG; METFORMIN HYDROCHLORIDE 850MG · TABLET, ORAL · Prescription · TE AB
  • JENTADUETO · LINAGLIPTIN 2.5MG; METFORMIN HYDROCHLORIDE 1GM · TABLET, ORAL · Prescription · TE AB
  • JENTADUETO · LINAGLIPTIN 2.5MG; METFORMIN HYDROCHLORIDE 500MG · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Linagliptin" as an intervention, any sponsor and status, largest first.

All 195 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • blood glucose increased93
  • diarrhoea90
  • nausea67
  • vomiting58
  • drug ineffective53
  • fatigue45
  • off label use45
  • pain43
  • dizziness42
  • headache41
  • arthralgia40
  • acute kidney injury38

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
201238
201379
2014106
2015118
2016111
2017116
2018109
2019115
202072
202182
202268
202364
202462
202539
202622

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Jentadueto (Linagliptin/Metformin HCl)

2024 spending

$83.4M

Beneficiaries

20,230

106,443 claims

Per beneficiary

$4,123

$8.36 per unit

View as table
YearSpending
2020$93,795,943
2021$93,753,019
2022$94,461,865
2023$93,638,309
2024$83,415,905

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 231 on PubMed

Sponsor: Boehringer Ingelheim

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.